Effects of time to treatment initiation on outcomes for soft tissue sarcomas.
extremities
humans
sarcoma
soft tissue neoplasms
time-to-treatment
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
23
01
2023
accepted:
01
03
2023
medline:
28
4
2023
pubmed:
21
3
2023
entrez:
20
3
2023
Statut:
ppublish
Résumé
Few studies have investigated the effects of time to treatment initiation (TTI) for soft tissue sarcomas (STS). Our objective was to investigate the risk factors for prolonged TTI and the effects of prolonged TTI on local recurrence free survival (LRFS), distant metastasis free survival (DMFS), and disease specific survival (DSS). Patients diagnosed with high-grade STS of the extremities and trunk from 2011 to 2020 were included. TTI was grouped into two groups (treatment provided in less than vs. more than or equal to 30 days). Two-year and 5-year survival probabilities were calculated for LRFS, DMFS, and DSS. Cox regression and Kruskal-Wallis tests in univariate analysis were conducted to find risk factors affecting TTI and the survival outcomes. In the univariate analysis, diagnosis in the later 5-year period of the study, tumor size, and treatment modality were associated with prolonged TTI. TTI ≥30 days was associated with higher DMFS but no association was found with LRFS or DSS. Tumor size, surgical margins, and provision of surgery were associated with DSS. Despite the delay in treatment for STS patients caused by the COVID-19 pandemic, our study showed TTI of more than 30 days does not negatively impact patients.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Few studies have investigated the effects of time to treatment initiation (TTI) for soft tissue sarcomas (STS). Our objective was to investigate the risk factors for prolonged TTI and the effects of prolonged TTI on local recurrence free survival (LRFS), distant metastasis free survival (DMFS), and disease specific survival (DSS).
METHOD
METHODS
Patients diagnosed with high-grade STS of the extremities and trunk from 2011 to 2020 were included. TTI was grouped into two groups (treatment provided in less than vs. more than or equal to 30 days). Two-year and 5-year survival probabilities were calculated for LRFS, DMFS, and DSS. Cox regression and Kruskal-Wallis tests in univariate analysis were conducted to find risk factors affecting TTI and the survival outcomes.
RESULTS
RESULTS
In the univariate analysis, diagnosis in the later 5-year period of the study, tumor size, and treatment modality were associated with prolonged TTI. TTI ≥30 days was associated with higher DMFS but no association was found with LRFS or DSS. Tumor size, surgical margins, and provision of surgery were associated with DSS.
CONCLUSION
CONCLUSIONS
Despite the delay in treatment for STS patients caused by the COVID-19 pandemic, our study showed TTI of more than 30 days does not negatively impact patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1174-1186Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Kumar D. Pathology of bone and soft tissue sarcomas. Sarcoma. 2017;1:23-41.
Elliott RS, Flint M, French G. Refer prior to biopsy of suspected appendicular soft tissue sarcoma. N Z Med J. 2012;125(1366):12-19.
Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70(3):200-229. doi:10.3322/caac.21605
Featherall J, Curtis GL, Lawrenz JM, et al. Time to treatment initiation and survival in adult localized, high-grade soft tissue sarcoma. J Surg Oncol. 2019;120(7):1241-1251. doi:10.1002/jso.25719
Ogura K, Fujiwara T, Healey JH. Patients with an increased time to treatment initiation have a poorer overall survival after definitive surgery for localized high-grade soft-tissue sarcoma in the extremity or trunk. Bone Joint J. 2021;103-B(6):1142-1149. doi:10.1302/0301-620X.103B6.BJJ-2020-2087.R1
Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087. doi:10.1136/bmj.m4087
Guirado M, Fernández Martín E, Fernández Villar A, Navarro Martín A, Sánchez-Hernández A. Clinical impact of delays in the management of lung cancer patients in the last decade: systematic review. Clin Transl Oncol. 2022;24(8):1549-1568. doi:10.1007/s12094-022-02796-w
Murphy CT, Galloway TJ, Handorf EA, et al. Survival impact of increasing time to treatment initiation for patients with head and neck cancer in the United States. J Clin Oncol. 2016;34(2):169-178. doi:10.1200/JCO.2015.61.5906
Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and breast cancer survival in the United States. JAMA Oncol. 2016;2(3):330. doi:10.1001/jamaoncol.2015.4508
Biermann JS, Siegel G, Chugh R, et al. The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework. J Multidiscip Healthc. 2015;8:109-115. doi:10.2147/JMDH.S49805
Blay JY, Soibinet P, Penel N, et al. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017;28:2852-2859. doi:10.1093/annonc/mdx484
National Comprehensive Cancer Network. Soft tissue sarcoma. Version 2. National Comprehensive Cancer Network. 2018.
Gustafson P, Dreinhofer KE, Rydholm A. Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand. 1994;65(47):47-50. doi:10.3109/17453679408993717
Gutierrez JC, Perez EA, Moffat FL, Livingstone AS, Franceschi D, Koniaris LG. Should soft tissue sarcomas be treated at high-volume centers. Ann Surg. 2007;245:952-958. doi:10.1097/01.sla.0000250438.04393.a8
Hoekstra HJ, Haas RLM, Verhoef C, et al. Adherence to guidelines for adult (Non-GIST) soft tissue sarcoma in the Netherlands: a plea for dedicated sarcoma centers. Ann Surg Oncol. 2017;24:3279-3288. doi:10.1245/s10434-017-6003-3
Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679-1689. doi:10.1200/JCO.1996.14.5.1679
Jang WY, Kim HS, Han I. Impact of surgical margin on survival in extremity soft tissue sarcoma. Medicine. 2021;100(3):e24124. doi:10.1097/MD.0000000000024124
Chao AH, Mayerson JL, Chandawarkar R, Scharschmidt TJ. Surgical management of soft tissue sarcomas: extremity sarcomas. J Surg Oncol. 2014;111(5):540-545. doi:10.1002/jso.23810
Koshy M, Rich SE, Mohiuddin MM. Improved survival with radiation therapy in high-grade soft tissue sarcomas of the extremities: a SEER analysis. Int J Radiation Oncol*Biol*Phy. 2010;77(1):203-209. doi:10.1016/j.ijrobp.2009.04.051
Gingrich AA, Bateni SB, Monjazeb AM, et al. Neoadjuvant radiotherapy is associated with R0 resection and improved survival for patients with extremity soft tissue sarcoma undergoing surgery: a national cancer database analysis. Ann Surg Oncol. 2017;24(11):3252-3263. doi:10.1245/s10434-017-6019-8
Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197-203. doi:10.1200/JCO.1998.16.1.197
O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359:2235-2241. doi:10.1016/S0140-6736(02)09292-9
Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859-868. doi:10.1200/JCO.1996.14.3.859
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573-581. doi:10.1002/cncr.23592
Beadel G. Treating soft tissue sarcomas. N Z Med J. 2012;125(1366):9-11.
Alcindor T, Dumitra S, Albritton K, Thomas DM. Disparities in cancer care: the example of sarcoma-in search of solutions for a global issue. Am Soc Clin Oncol Educational Book. 2021;41:405-411. doi:10.1200/EDBK_320463
Cancer Australia. Review of the impact of COVID-19 on medical services and procedures in Australia utilising MBS data: skin, breast and colorectal cancers, and telehealth services. 2020.
Parmar A, Eskander A, Sander B, Naimark D, Irish JC, Chan KKW. Impact of cancer surgery slowdowns on patient survival during the COVID-19 pandemic: a microsimulation modelling study. Can Med Assoc J. 2022;194(11):E408-E414. doi:10.1503/cmaj.202380
Malagón T, Yong JHE, Tope P, Miller WH, Franco EL. Predicted long-term impact of COVID -19 pandemic-related care delays on cancer mortality in Canada. Int J Cancer. 2021;150(8):1244-1254. doi:10.1002/ijc.33884
WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. WHO Classification of Tumours Series. Vol 3, 5th ed. International Agency for Research on Cancer. https://publications.Iarc.fr/588
Ministry of Health. Faster Cancer Treatment Indicators: Use Cases. Ministry of Health; 2014.
Al-Absi E, Farrokhyar F, Sharma R, et al. A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. Ann Surg Oncol. 2010;17(5):1367-1374. doi:10.1245/s10434-009-0885-7
Larrier NA, Czito BG, Kirsch DG. Radiation therapy for soft tissue sarcoma. Surg Oncol Clin N Am. 2016;25(4):841-860. doi:10.1016/j.soc.2016.05.012
DeMore NK, Savage SJ, Lesher AP, et al. What is elective oncologic surgery in the time of COVID-19? A literature review of the impact of surgical delays on outcomes in patients with cancer. Clin Oncol Res. 2020;3(6):1-11. doi:10.31487/j.COR.2020.06.05
Penel N, Bonvalot S, Minard V, et al. French sarcoma group proposals for management of sarcoma patients during the COVID-19 outbreak. Ann Oncol. 2020;31(7):965-966. doi:10.1016/j.annonc.2020.03.308
Sacchetti F, Alsina AC, Morganti R, et al. Re-excision after unplanned excision of soft tissue sarcoma: a systematic review and metanalysis. J Orthop. 2021;25:244-251. doi:10.1016/j.jor.2021.05.022